Prevention of Esophageal Variceal Rebleeding
Esophageal Variceal Rebleeding
Enrolment: 120 · Results not recorded
Loading the evidence…
Drug · Vasopressin V1 receptor binding agent (BINDING AGENT); Vasopressin V2 receptor binding agent (BINDING AGENT)
2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Esophageal Variceal Rebleeding
Enrolment: 120 · Results not recorded
Esophageal Varices · Bleeding
Enrolment: 118 · Results not recorded
Hepatorenal Syndrome
Enrolment: 112 · Results not recorded
Hepatorenal Syndrome
Enrolment: 50 · Results not recorded
Hepatorenal Syndrome
Enrolment: 300 · Results not recorded
Septic Shock · Sepsis-associated Hypotension
Enrolment: 21 · Results not recorded
Hemoptysis
Enrolment: 315 · Results not recorded
Cirrhosis · Type 1 Hepatorenal Syndrome
Enrolment: 70 · Results not recorded
Septic Shock · Sepsis
Enrolment: 60 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute mesenteric ischaemia-reperfusion: superior mesenteric artery clamped with a microaneurysm clip for 1 h followed by reperfusion, under pentobarbital anaesthesia (30 mg/kg intraperitoneally) and mechanical ventilation, with midline laparotomy
Terlipressin and norepinephrine both restored mean arterial pressure, reduced intestinal and renal injury scores, lowered blood urea nitrogen and creatinine, and improved survival compared with untreated mesenteric ischaemia (mortality 85.7% with a median survival of 3 h). Only terlipressin reduced…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.